D&D Pharmatech Inc. Logo

D&D Pharmatech Inc.

Develops oral & injectable peptide therapies for metabolic & chronic diseases like obesity.

347850 | KO

Overview

Corporate Details

ISIN(s):
KR7347850000
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 금토로80번길 27 (금토동, 텔레칩스) 4층, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

D&D Pharmatech Inc. is a clinical-stage global biotechnology company focused on developing novel peptide-based therapies for metabolic and chronic diseases with high unmet medical needs. The company's core research centers on its portfolio of GLP-1 (Glucagon-like peptide-1) class drugs, targeting conditions such as obesity and MASH (Metabolic dysfunction-associated steatohepatitis). A key competency is its advanced oral peptide technology, which enables the creation of oral treatments in addition to injectable therapies. D&D Pharmatech operates a dual-center model, with a research team in Korea dedicated to peptide discovery and a clinical development team in the United States managing global trials and regulatory processes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-16 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-07-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.4 KB
2025-06-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 180.8 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.1 KB
2025-06-19 00:00
Regulatory News Service
기타경영사항(자율공시) (국책과제 선정(국가신약개발사업(R&D) (대사이상 관련 지방간염(MASH) 치료제 DD01 개…
Korean 7.9 KB
2025-06-17 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-06-16 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (대사이상지방간염 (MASH) 치료제 DD01의 미국 임상 제2상 Topline …
Korean 12.8 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-06-11 00:00
Capital/Financing Update
주요사항보고서(자본으로인정되는채무증권발행결정)
Korean 31.4 KB

Automate Your Workflow. Get a real-time feed of all D&D Pharmatech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for D&D Pharmatech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for D&D Pharmatech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MBX Biosciences, Inc. Logo
Developing novel peptide therapies for underserved endocrine and metabolic disorders.
United States of America
MBX
Median Diagnostics Inc. Logo
Manufactures veterinary IVD kits & raw materials to diagnose infectious animal diseases.
South Korea
233250
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan
4875
Medicon Hellas S.A. Logo
Develops, makes, and sells IVD products, analytical systems & software for healthcare providers.
Greece
MEDIC
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea
054180
Medicus Pharma Ltd. Logo
A clinical-stage holding company advancing novel drugs, biologics, and devices to market.
United States of America
MDCX
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany
MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France
MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan
2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany
ILM1

Talk to a Data Expert

Have a question? We'll get back to you promptly.